Non-Muscle Invasive Bladder Cancer Pipeline as Novel and Extensive 30+ Therapies Likely to Enter in the Treatment Domain
DelveInsight’s, “Non Muscle Invasive Bladder Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Non Muscle Invasive Bladder Cancer Pipeline Insight Report
- DelveInsight’s Non Muscle Invasive Bladder Cancer Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Non Muscle Invasive Bladder Cancer.
- The leading Non Muscle Invasive Bladder Cancer Companies are working such as Tollys, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, Bristol-Myers Squibb, Asieris Pharmaceuticals, UroGen Pharma, CG Oncology, Sesen Bio, Hamlet Pharma, AstraZeneca, Viralytics, ImmunityBio, Prokarium, Abraxis Bioscience, LIPAC Oncology, Rapamycin Holdings, Taizhou Hanzhong Biomedical, Spectrum Pharmaceuticals, FKD therapies, Altor Biosciences, Heat Biologics, EMD Sereno, QED Therapeutics, and many others.
- Essential Non-Muscle Invasive Bladder Cancer pipeline therapies such as TL-532, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, Sasanlimab/PF-06801591, Nivolumab, APL-1202, UGN-102, Vesibax, and others are under development in different phases of clinical trials.
- The Non Muscle Invasive Bladder Cancer Companies and academics are working to assess challenges and seek opportunities that could influence Non Muscle Invasive Bladder Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Non Muscle Invasive Bladder Cancer.
Recent Developmental Activities in the Non-Muscle Invasive Bladder Cancer Pipeline
- In November 2021, preliminary Phase II study (CORE1) results were presented for CG0070 in combination with KEYTRUDA® (pembrolizumab), for the treatment of patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG). Results showed that a combination of CG0070 and pembrolizumab was well tolerated with encouraging early efficacy data in 9 patients.
- In October 2021, Asieris Pharmaceuticals initiated a Multi-center, Randomized, Open-label, Parallel-controlled Phase 3 Clinical Trial to Evaluate the Clinical Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk Non-muscle Invasive Bladder Cancer patients.
- UGN-102 (mitomycin gel) is an investigational formulation that utilizes our innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. UGN-102 is in Phase III clinical evaluation for the treatment of Non-Muscle Invasive Bladder Cancer.
- Sasanlimab (PF-06801591) is an immunotherapy that Pfizer is developing for several types of cancer. It is called an anti-PD-1 treatment because it blocks the PD-1 protein on the surface of immune T-cells that can sometimes attack healthy cells.
- In June 2021, LiPax, a precision-targeted, locally-delivered taxane being developed by Lipac oncology was found to induce a recurrence-free survival rate of 83% in patients with Non–Muscle Invasive bladder cancer who had undergone transurethral resection of bladder tumor.
Request a sample and discover more about the Non-Muscle Invasive Bladder Cancer pipeline report offerings @ Non-Muscle Invasive Bladder Cancer Pipeline Outlook Report
Non-Muscle Invasive Bladder Cancer Overview
Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. NMIBC accounts for 75% of all newly diagnosed cases of urothelial carcinoma of the bladder. Some of the common symptoms are hematuria (blood in the urine), frequent and urgent urination, pain in lower abdomen, and back pain. The diagnosis of bladder cancer is confirmed by direct visualization of the tumor and other mucosal abnormalities with endoscopic excision using cystoscopy and TURBT. The main treatments for when the cancer cells are found only in the bladder’s inner lining (non-muscle-invasive bladder cancer) are surgery, immunotherapy and intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Superficial, non-muscle invasive bladder cancers (NMIBCs) are managed with cystoscopic transurethral resection of all visible lesions followed by intravesical chemotherapy and/or immunotherapy.
Non-Muscle Invasive Bladder Cancer Pipeline Report
In the Non-Muscle Invasive Bladder Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non Muscle Invasive Bladder Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Non-Muscle Invasive Bladder Cancer Emerging Drugs Profile
UGN-102: UroGen Pharma
UGN-102 (mitomycin gel) is an investigational formulation that utilizes our innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. UGN-102 is in Phase III clinical evaluation for the treatment of Non Muscle Invasive Bladder Cancer.
Sasanlimab: Pfizer
Sasanlimab (PF-06801591) is an immunotherapy that Pfizer is developing for several types of cancer. It is called an anti-PD-1 treatment because it blocks the PD-1 protein on the surface of immune T-cells that can sometimes attack healthy cells. PD-1 is an immune checkpoint protein that prevents T-cells from attacking healthy cells. Healthy cells produce a protein called PD-L1 that binds to PD-1, inactivating T-cells. Pfizer is developing PF-06801591 for the treatment of Non-muscle Invasive Bladder Cancer and is currently in phase III stage of development.
Find out more about the disease and recent developments in Non-Muscle Invasive Bladder Cancer Pipeline @ Non-Muscle Invasive Bladder Cancer Ongoing Clinical Trials Analysis
Scope of the Non-Muscle Invasive Bladder Cancer Pipeline
- Coverage- Global
- Non Muscle Invasive Bladder Cancer Companies are working such as Tollys, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, Bristol-Myers Squibb, Asieris Pharmaceuticals, UroGen Pharma, CG Oncology, Sesen Bio, Hamlet Pharma, AstraZeneca, Viralytics, ImmunityBio, Prokarium, Abraxis Bioscience, LIPAC Oncology, Rapamycin Holdings, Taizhou Hanzhong Biomedical, Spectrum Pharmaceuticals, FKD therapies, Altor Biosciences, Heat Biologics, EMD Sereno, QED Therapeutics, and many others.
- Non-Muscle Invasive Bladder Cancer pipeline therapies such as TL-532, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, Sasanlimab/PF-06801591, Nivolumab, APL-1202, UGN-102, Vesibax, and others
- Non-Muscle Invasive Bladder Cancer Emerging Therapies, Unmet Needs, Analyst Views
Table of Content
- Introduction
- Non Muscle Invasive Bladder Cancer Executive Summary
- Non Muscle Invasive Bladder Cancer: Overview
- Non Muscle Invasive Bladder Cancer Pipeline Therapeutics
- Non Muscle Invasive Bladder Cancer Therapeutic Assessment
- Non Muscle Invasive Bladder Cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- UGN-102: UroGen Pharma
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- TLD 1433: Theralase Technologies
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- VAX-014: Vaxiion Therapeutics
- Drug profiles in the detailed report…..
- Preclinical/Discovery Stage Products
- Vesibax: Prokarium
- Drug profiles in the detailed report…..
- Inactive Products
- Non Muscle Invasive Bladder Cancer Key Companies
- Non Muscle Invasive Bladder Cancer Key Products
- Non Muscle Invasive Bladder Cancer- Unmet Needs
- Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
- Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
- Non Muscle Invasive Bladder Cancer Analyst Views
- Appendix
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Non Muscle Invasive Bladder Cancer drugs?
- How many Non Muscle Invasive Bladder Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non Muscle Invasive Bladder Cancer?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Non Muscle Invasive Bladder Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Non Muscle Invasive Bladder Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
Learn more about the novel and emerging Non-Muscle Invasive Bladder Cancer pipeline therapies @ Non-Muscle Invasive Bladder Cancer Treatment Landscape
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/
